OPEN ACCESS Freely available online

ISSN: 2157-7560
Journal of
Vaccines & Vaccination

Commentary

Functions of Lipids in mRNA vaccines

Sarah Lynn*

Department of Immunology, University of Toronto, Toronto, Canada

DESCRIPTION

Vaccines efficacy in mRNA combating various types of cancer and infectious pathogens where conventional vaccine platforms may fail to induce protective immune responses. Vaccination is the most effective medical method for disease prevention and control. Vaccine development and use have saved thousands of lives as well as large sums of money. Vaccines have the potential to be used not only against infectious diseases, but also as a prophylactic and treatment tool for cancer, as well as for allergen elimination. Vaccines were created to protect against pathogenic microorganisms. Inactivated vaccines were generally developed in animals, cell lines, or under unfavorable growth conditions, while live attenuated vaccines were generally developed in animals, cell lines, or under unfavorable growth conditions. The mechanisms involved in conferring immunity were unknown during vaccine development. Nonetheless, the use of live attenuated or killed whole organism-based vaccines has had enormous success in the control and eradication of a number of severe human infectious diseases, including smallpox, polio, measles, mumps, and rubella, as well as animal infectious diseases such as classic swine fever, cattle plague, and equine infectious anaemia. Because of advances in molecular biology theory and technology, live attenuated, subunit and peptide-based vaccines have recently been developed. The results of live attenuated vaccination significantly increased our understanding of the mechanisms underlying the immune response elicited by these vaccines. Antigen-specific antibodies play a significant role in the prevention and control of microbe-initiated infectious disease in the case of inactivated vaccines.

FUNCTION OF LIPIDS

Lipid Nanoparticles (LNPs) are spherical vesicles with a uniform lipid core. Naked mRNA is unstable, but when encased in an LNP bubble, it is sufficiently protected to be transported into cells and unpackaged. Liposomes early versions of LNPs have already proven to be an effective nano-medicine delivery platform, with several liposomal drugs approved and used in clinical practice.

Although subsequent generations of lipid nano carriers have more complex architectures and improved physical stabilities, nanostructured lipid carriers and solid LNPs have become the preferred drug delivery platforms for antitumor and nucleic acid therapeutics, as well as vaccine delivery systems. COVID-19 vaccines have been developed using a variety of techniques. Among these, the COVID-19 messenger RNA (mRNA) vaccine has received increased attention due to its broad application potential and benefits, which include a short development cycle, ease of industrialization, a simple manufacturing process, the ability to respond to new variants, and the ability to induce a stronger immune response. mRNA vaccines have been extensively studied for infectious disease prevention as well as cancer prophylaxis and therapy. So far, much progress has been made. Cancer mRNA vaccines were created with the goal of expressing tumor-associated antigens that stimulate cell-mediated immune responses that kill or inhibit cancer cells. Prophylactic or therapeutic mRNA vaccines against infectious diseases could be developed. mRNA vaccines that express an infectious pathogen's antigen elicit both strong and potent T cell and humoral immune responses. As previously stated, the procedure for producing mRNA vaccines is completely cell-free, simple, and fast when compared to the production of whole microbe, live attenuated, and subunit vaccines. Because of its quick and easy manufacturing process, mRNA is a promising bio-product that has the potential to bridge the gap between emerging infectious diseases and the desperate need for effective vaccines.

Correspondence to: Sarah Lynn, Department of Immunology, University of Toronto, Toronto, Canada, E-mail: sarahlynn@uni.edu.ca

Received: 02-Jan-2023, Manuscript No. JVV-23-19915; **Editor assigned:** 04-Jan-2023, Pre QC No. JVV-23-19915 (PQ); **Reviewed:** 19-Jan-2023, QC No JVV-23-19915; **Revised:** 27-Jan-2023, Manuscript No. JVV-23-19915 (R); **Published:** 03-Feb-2023, DOI: 10.35248/2157-7560.23.14.507.

Citation: Lynn S (2023) Functions of Lipids in mRNA vaccines. J Vaccines Vaccin. 14:507.